Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPH3127 in Mild to Moderate Ulcerative Colitis
NCT05770609Phase 2Completed
- Sponsor
- Shanghai Pharmaceuticals Holding Co Ltd
- Start
- Jun 2023
- Primary completion
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sitokiren in ulcerative colitis (UC), sponsored by Shanghai Pharmaceuticals Holding Co Ltd. Started Jun 2023; status: completed.
02
Drugs
sitokiren
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT05770609.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05770609.